3 ms·
Another issue is, other targets may not provide neutralizing immunity and may facilitate ADE. I don't think we've seen ADE in natural infection yet, so it may
by anonuser123456 5y ago
Another issue is, other targets may not provide neutralizing immunity and may facilitate ADE. I don't think we've seen ADE in natural infection yet, so it may just be a theoretical issue, but I also don't know if we've really looked for ADE in natural infection either.
We do know that other similar coronavirus vaccine candidates (a candidate for SARS-COV-1) exhibited ADE in primate studies. So since the spike protein appears effective currently, maybe it's best to stick with that.
- raphlinus 5y agoFor people curious about ADE (a fascinating topic that so far doesn't seem to have caused problems with SARS-CoV-2), here is some excellent background reading that covers many of the points made in the above comment, with citations and deeper discussion: https://blogs.sciencemag.org/pipeline/archives/2021/02/12/antibody-dependent-enhancement-and-the-coronavirus-vaccines https://blogs.sciencemag.org/pipeline/archives/2021/02/12/an...
- anonuser123456 5y agoI remember when this whole thing originally broke out, ADE was my biggest fear. Even when China was talking about a 2-3% infection fatality rate, it's like ok.. well that's not going to shatter society. But ADE... the prospect that getting it a 2nd time would raise the IFR to who knows... 20+%? That was scary.